stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) Total debt
Arcutis Biotherapeutics, Inc.'s total debt at the end of fiscal 2025 was $109.0M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $109.4M. Over the past ten years it has ranged from $307.0K (fiscal 2019) to $201.8M (fiscal 2023); the current reading is higher than 71% of that period. Arcutis Biotherapeutics, Inc. ranks 80th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $109.0M | 1.64% |
| FY2024 | $107.2M | (46.88%) |
| FY2023 | $201.8M | 1.70% |
| FY2022 | $198.4M | 172.63% |
| FY2021 | $72.8M | 1,366.22% |
| FY2020 | $5.0M | 1,516.94% |
| FY2019 | $307.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $109.4M | 0.46% |
| Jun 2026 | $108.9M | (0.48%) |
| Mar 2026 | $109.4M | 0.42% |
| Dec 2025 | $109.0M | 0.42% |
| 24 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | $156.4M |
| ARQT Arcutis Biotherapeutics, Inc. | $109.4M |
| ABCL AbCellera Biologics Inc. compare | $81.0M |
| RLAY Relay Therapeutics, Inc. compare | $55.0M |
| TNGX Tango Therapeutics, Inc. compare | $39.5M |
| DFTX Definium Therapeutics, Inc. compare | $36.5M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| IOVA Iovance Biotherapeutics, Inc. compare | $1.0M |
| DNTH Dianthus Therapeutics, Inc. compare | $670.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement